NuCana PLC (NCNA)

NASDAQ: NCNA · IEX Real-Time Price · USD
1.67
+0.04 (2.45%)
Aug 16, 2022 11:20 AM EDT - Market open
2.45%
Market Cap 87.17M
Revenue (ttm) n/a
Net Income (ttm) -51.55M
Shares Out 52.20M
EPS (ttm) -0.92
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 46,538
Open 1.60
Previous Close 1.63
Day's Range 1.55 - 1.67
52-Week Range 0.52 - 3.32
Beta 1.22
Analysts Buy
Price Target 9.44 (+465.3%)
Earnings Date Aug 17, 2022

About NCNA

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian canc... [Read more...]

Industry Biotechnology
IPO Date Sep 28, 2017
CEO Hugh Griffith
Employees 31
Stock Exchange NASDAQ
Ticker Symbol NCNA
Full Company Profile

Financial Performance

Financial numbers in GBP Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for NCNA stock is "Buy." The 12-month stock price forecast is 9.44, which is an increase of 465.27% from the latest price.

Price Target
$9.44
(465.27% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Why NuCana Shares Are Rising Today?

Regional Court of Dusseldorf has ruled in favor of NuCana plc (NASDAQ: NCNA), stating that Gilead Sciences Ireland UC and Gilead Sciences GmbH infringed NuCana's composition of matter claims in European...

German Court Rules that Gilead's Sofosbuvir Infringes NuCana's ‘190 Patent

EDINBURGH, United Kingdom, July 11, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that, following a comprehensive hearing on May 17, 2022, the Regional Court of Dusseldorf (the “Court”) i...

NuCana Announces Presentation on NUC-7738 at the European Hematology Association (EHA) 2022 Hybrid Congress

NUC-7738 Shows Promising Non-Clinical Activity in Acute Myeloid Leukemia

NuCana Announces Receipt of NASDAQ Notice

EDINBURGH, United Kingdom, June 03, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that it received written notification (the “Notification Letter”) from The Nasdaq Stock Market LLC ("Nasd...

NuCana Reports First Quarter 2022 Financial Results and Provides Business Update

Initiated Randomized Phase 2 Study of NUC-3373 in Patients with Colorectal Cancer

NuCana to Participate in the 2022 Jefferies Healthcare Conference

EDINBURGH, United Kingdom, June 01, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Don Munoz, Chief Financial Officer, will host one-on-one meetings at the Jefferies Healthcare ...

NuCana Reports Fourth Quarter and Year Ended 2021 Financial Results and Provides Business Update

Optimizes Development Strategy with Study Initiations and Data Announcements Expected throughout 2022

NuCana Announces Upcoming Presentations on NUC-3373 at the American Association for Cancer Research (AACR) Annual Mee...

Checkpoint Inhibitor Nivolumab Activity Enhanced by NUC-3373 in vitro

Down 57.3% in 4 Weeks, Here's Why You Should You Buy the Dip in NuCana PLC Sponsored ADR (NCNA)

NuCana PLC Sponsored ADR (NCNA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analyst...

NuCana Announces Update for Phase 3 Biliary Tract Cancer Study

Independent Data Monitoring Committee Recommended Study be Discontinued Following Futility Assessment Conducted at First Interim Analysis

NuCana to Participate in Two Upcoming Investor Conferences

EDINBURGH, United Kingdom, Feb. 28, 2022 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will participa...

NuCana Announces Enrollment of Required Number of Patients to Conduct Second Interim Analysis in the Phase III Biliar...

Enrollment of 644 Evaluable Patients Expected to Enable Second Interim Analysis in the Second Half of 2022

Is NuCana PLC Sponsored ADR (NCNA) Outperforming Other Medical Stocks This Year?

Here is how NuCana PLC Sponsored ADR (NCNA) and OptiNose (OPTN) have performed compared to their sector so far this year.

NuCana Reports Third Quarter 2021 Financial Results and Provides Business Update

Enrolled Required Number of Patients to Conduct First Interim Analysis in Phase 3 Biliary Tract Cancer Study in the First Half of 2022

NuCana Appoints Elliott M. Levy, M.D.

Former Amgen SVP of Global Development and R&D Strategy and Operations Brings Substantial Drug Development Experience to NuCana Former Amgen SVP of Global Development and R&D Strategy and Operations Bri...

NCNA Stock: The Big Cancer Drug News Sending NuCana Skyrocketing

NuCana (NCNA) stock is surging higher on Wednesday after the company revealed fast track designation from the FDA for Acelarin. The post NCNA Stock: The Big Cancer Drug News Sending NuCana Skyrocketing ...

Why Are NuCana Shares Moving Higher On Wednesday?

The FDA has granted Fast Track designation to NuCana plc's (NASDAQ: NCNA) Acelarin (NUC-1031) for the first-line treatment of patients with advanced biliary tract cancer. The Company recently announced ...

NuCana Receives Fast Track Designation from the U.S. Food and Drug Administration for Acelarin® (NUC-1031) for the Tr...

EDINBURGH, United Kingdom, Sept. 29, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Acelarin (NUC-103...

NuCana Announces Four Poster Presentations at the ESMO Congress 2021

NUC-3373 Continues to Demonstrate Encouraging Efficacy Signals and a Favorable Safety Profile in Patients with Advanced Colorectal Cancer

NuCana Announces Enrollment of Required Number of Patients to Conduct First Interim Analysis in the Phase III Biliary...

Enrollment of 418 Evaluable Patients Expected to Enable First Interim Analysis in the First Half of 2022

7 Bargain Stocks to Buy Under $5 With the Right Catalysts

The risk in these inexpensive bargain stocks is offset by their upside for investors looking for a little more spice in their portfolio. The post 7 Bargain Stocks to Buy Under $5 With the Right Catalyst...

NuCana Reports Second Quarter 2021 Financial Results and Provides Business Update

EDINBURGH, United Kingdom, Aug. 19, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the second quarter ended June 30, 2021 and provided an update on its broad clinical...

7 Penny Stocks to Buy if You Want Potential Multibaggers

Here's a list of interesting penny stocks to buy that have lucrative prospects if you're willing to risk it for tremendous upside. The post 7 Penny Stocks to Buy if You Want Potential Multibaggers appea...

Other symbols: COECRNTRMTISTMH

NuCana Reports First Quarter 2021 Financial Results and Provides Business Update

Presented Encouraging Clinical Data at ASCO-GI and AACR

NuCana to Participate in the 7th Annual Truist Securities Life Sciences Summit

EDINBURGH, United Kingdom, April 28, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will host one...